Recent Updates
Recently added Catalysts

AZD2389

Phase 2

Liver Fibrosis | Small molecule | Gastrointestinal |AstraZeneca PLC|Last Updated: Sep 1, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials3
Total Enrollment152

FDA Designations

No designations recorded

Clinical trial landscape

AZD2389 · 8 trials · 5 indications

Phase 2 2Phase 1 6
NCT07610837Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisLiver Fibrosis
RECRUITING104 Analytics
NCT06750276A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.Liver Fibrosis
COMPLETED40 Analytics
PHASE2RECRUITING
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Liver FibrosisUnlock trial analytics
PHASE2COMPLETED
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
Liver FibrosisUnlock trial analytics

Study Endpoints

Primary Endpoints

Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24
24 weeks

To evaluate the effects of AZD2389 versus placebo on improvement in ELF score. Lowered ELF scores would suggest better outcome. Note: ELF is not bounded, i.e. there are no minimum and maximum values

Reported quantity and severity of adverse events (AEs)
Up to and including Day 197

To assess the safety and tolerability of AZD2389 in participants with SLD and advanced fibrosis

Number of participants with observed changes in blood pressure against baseline mmHg value
Up to and including Day 197

Assess blood pressure level (with systolic and diastolic pressure) in mmHg

Number of participants with identified abnormalities in results of 12-lead safety electrocardiograms (ECG)
Up to and including Day 197

12-lead safety ECG (PR interval, QRS complex, ST interval, T wave)

Number of participants with abnormal laboratory results detected in urine samples
Up to and including Day 197

Urinalysis - Paper chromatography

Number of participants with observed changes in heart rate (BPM) against baseline value
Up to and including Day 197

Pulse rate measured in beats per minute (BPM)

Number of participants with observed changes in Sp02 oxygen values against baseline measurement
Up to and including Day 197

Sp02 oxygen saturations measured by percentage

Number of participants with observed changes in body temperature against baseline value
Up to and including Day 197

Body temperature measured in degrees Celsius

Number of participants with observed changes in respiratory rate against baseline value
Up to and including Day 197

Respiratory rate measured in respirations per minute

Number of participants with abnormal laboratory test results detected in blood samples
Up to and including Day 197

Hematology - Platelets (x10\^9/L)

Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)
From screening up to and including Day 35

The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria.

Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)
From Screening up to and including Day 35

The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities.

Occupancy, %: percent change from baseline in uptake of FAP PET radioligand [68Ga]Ga-FAPI-46 in the liver after a single dose of AZD2389.
PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

To examine target FAP occupancy in the liver by AZD2389 as measured with \[68Ga\]Ga-FAPI-46 PET.

Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on maximum observed plasma concentration (RCmax)
Day 1 to Day 10

To assess the effect of quinidine on the PK of AZD2389.

Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to infinity (RAUCinf)
Day 1 to Day 10

To assess the effect of quinidine on the PK of AZD2389.

Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)
Day 1 to Day 10

To assess the effect of quinidine on the PK of AZD2389.

Ratio of treatment to reference based on Cmax (RCmax)
Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

To assess the PK parameter RCmax for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

Ratio of treatment to reference based on AUCinf (RAUCinf)
Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

To assess the PK parameter RAUCinf for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

Ratio of treatment to reference based on AUClast (RAUClast)
Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

To assess the PK parameter RAUClast for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

Ratio of area under concentration-curve from time 0 to 24 hours post-dose (AUC0-24)
Period 1: Days 1-3; Period 3: Days 15-18.

To assess the PK parameter ratio of AUC0-24 for caffeine in combination with AZD2389 compared to caffeine alone.

Maximum observed drug concentration (Cmax) of AZD2389
Day 1 to Day 8

To assess the effect of itraconazole on the Cmax of AZD2389.

Area under concentration-timecurve from time zero to infinity (AUCinf) of AZD2389
Day 1 to Day 8

To assess the effect of itraconazole on the AUCinf of AZD2389.

Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD2389
Day 1 to Day 8

To assess the effect of itraconazole on the AUClast of AZD2389.

Plasma PK parameter Cmax
pre-dose to 48 hours post-dose

maximum observed plasma concentration

Plasma PK parameter AUCinf
pre-dose to 48 hours post-dose

area under the concentration-time curve from zero to infinity

Plasma PK parameter AUClast
pre-dose to 48 hours post-dose

area under the concentration-time curve from zero to the last measurable concentration

Part A (SAD): Number of participants with adverse events (AE) and serious adverse events (SAE)
Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 and 2, Day 8 Post-dose (± 1 day)

To assess the safety and tolerability of AZD2389 following oral administration of single ascending doses in healthy participants, including Japanese and Chinese participants.

Part B (MAD): Number of participants with AE and SAE
Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 to 12, Day 17 (± 1 day)

To assess the safety and tolerability of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.

Secondary Endpoints

Absolute change in Procollagen Type III N-terminal Propeptide (ProC3) from baseline to week 24
24 weeks
Absolute change in Liver Stiffness Measurement (LSM) from baseline to week 24
24 weeks
Absolute change in Controlled Attenuation Parameter (CAP) from baseline to week 24
24 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm AEXPERIMENTALDoses of AZD2389 to be administered orally.
Arm BPLACEBO_COMPARATORDoses of placebo to be administered orally.
Cohort AOTHERParticipants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
Cohort BOTHERParticipants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
Part AOTHERIn Part A, eligible participants (screening Visit 1) will return to the trial site for pre-assessments, confirmation of eligibility criteria, blood sampling for FAP concentration analysis (at the trial site), and the first PET examination (screening Visit 2). The participants will perform the PET examination at the PET Centre using the radioligand \[68Ga\]Ga-FAPI-46. Depending on the results of the initial PET examination, participants of Part A may be invited to continue the trial in Part B. In such a case they will participate in a total of 3 PET examinations, not exceeding predefined radiation exposure limits. If they do not participate further, they will complete the trial with a follow-up visit (Visit 3, telephone call) 7 days (±2 days) after the PET examination.
Part B1EXPERIMENTALIn Part B1, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.
Part B2EXPERIMENTALIn Part B2, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.
Part B3EXPERIMENTALIn Part B3, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.
Part CEXPERIMENTALIn Part C (optional), participants attend the trial site during Visit 1 (screening, Day-35 to Day-14) to undergo an eligibility check. At Visit 2, the first PET examination with radioligand will be performed at least 5 days before IMP administration. At Visit 3 (Day 1), participants receive a single dose AZD2389, then undergo a second PET examination using the radioligand on Day 2, along with blood sampling for PK analysis and FAP activity. At Visit 4 (Day 8 ±2 days), participants will be admitted to the trial site for a second single dose, then undergo a third PET examination using the radioligand on Day 9, along with blood sampling. At Visit 5 (7 days ±2 days after the PET examination on Visit 4) and Visit 6 (30 days \[+7 days\]) after the drug administration on Visit 4), follow-up visits at the trial site take place for safety monitoring and follow-up of any AEs.
Sequence ABEXPERIMENTALParticipants will receive a single dose of Treatment A (AZD2389) in Period 1 and a single dose of Treatment B (AZD2389 + quinidine) in Period 2.
Sequence BAEXPERIMENTALParticipants will receive a single dose of Treatment B (AZD2389 + quinidine) in Period 1 and a single dose of Treatment A (AZD2389) in Period 2.
Treatment ArmEXPERIMENTALIn Period 1, participants will receive midazolam and caffeine in combination on Day 1. Participants will receive bupropion on Day 2. In Period 2, participants will receive AZD2389 for 9 days from Day 5 to Day 13. In Period 3, participants will first receive AZD2389 with midazolam and caffeine in combination on Day 14. On Day 15, participants will first receive AZD2389 with bupropion. On Days 16 and 17, participants will receive AZD2389.
AZD2389 and ItraconazoleEXPERIMENTALAZD2389 is dosed on days 1 and 6. Itraconazole is dosed on days 3,4,5,6,7, with the dose on day 6 coming after AZD2389.
Cohort 1EXPERIMENTALParticipants with normal hepatic function (sex-, age-, and body mass index \[BMI\]-matched)
Cohort 2EXPERIMENTALParticipants with mild hepatic impairment (CP A classification)
Cohort 3EXPERIMENTALParticipants with moderate hepatic impairment (CP B classification)
Cohort 4EXPERIMENTALParticipants with severe hepatic impairment (CP C classification)
Cohort 1: Part A1 - AZD2389 dose 1/placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 2: Part A1 - AZD2389 dose 2/placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 3: Part A1 - AZD2389 dose 3 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 4: Part A1 - AZD2389 dose 4 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 5: Part A1 - AZD2389 dose 5 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 6: Part A1 - AZD2389 dose 6 oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389.
Cohort 7: Part A2 - AZD2389 dose 7 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 8: Part A2 - AZD2389 dose 8 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 9: Part A2 - AZD2389 dose 9 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 10: Part A3 - AZD2389 dose 10 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Cohort 11: Part B1 - AZD2389 dose 11 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Cohort 12: Part B1 - AZD2389 dose 12 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Cohort 13: Part B1 - AZD2389 dose 13 /placebo oral administrationEXPERIMENTALA total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Cohort 14: Part B2- AZD2389 dose 14/placebo oral administrationEXPERIMENTALA total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.

Interventions

NameTypeDescription
AZD2389DRUGpotent, selective, first-in-class, small molecule oral inhibitor of FAP and is being developed for the treatment of CLDs with advanced hepatic fibrosis including cirrhosis.
PlaceboOTHEROral administration
PET scan and radioligandDIAGNOSTIC_TESTPET scan and radioligand
QuinidineDRUGQuinidine will be administered orally.
MidazolamDRUGSingle oral dose on: * Day 1 (co-administered with caffeine) * Day 14 (co-administered with caffeine and AZD2389)
CaffeineDRUGSingle oral dose on: * Day 1 (co-administered with midazolam) * Day 14 (co-administered with midazolam and AZD2389)
BupropionDRUGSingle oral dose on: * Day 2 (alone) * Day 15 (co-administered with AZD2389)
ItraconazoleDRUGItraconazole is administered orally
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites20

Key Inclusion Criteria: * Males/females aged 18 or over * A diagnosis of SLD with advanced fibrosis * No significant change in weight over the last 6 months * Contraceptive us by participants or participants partners * Capable of giving informed consent * Judged by the investigator to be suitable f...

Countries:United StatesPuerto RicoUnited KingdomSweden
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 1, 2026NCT07610837lastUpdatePostDate: changed
LOWSep 1, 2026NCT07610837lastUpdatePostDate: changed
MEDIUMAug 27, 2026NCT07069725TRIAL_REMOVED: changed
MEDIUMAug 27, 2026NCT07069725TRIAL_REMOVED: changed
MEDIUMAug 27, 2026NCT07069725TRIAL_REMOVED: changed
MEDIUMAug 6, 2026NCT06750276TRIAL_REMOVED: changed
MEDIUMAug 6, 2026NCT06750276TRIAL_REMOVED: changed
MEDIUMAug 6, 2026NCT06750276TRIAL_REMOVED: changed
LOWJul 29, 2026NCT07610837lastUpdatePostDate: changed
LOWJul 29, 2026NCT07610837lastUpdatePostDate: changed
HIGHJul 27, 2026NCT07069725Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJul 27, 2026NCT07069725Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJul 27, 2026NCT07069725Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJul 2, 2026NCT07069725Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHJul 2, 2026NCT07069725Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHJul 2, 2026NCT07069725Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHJul 2, 2026NCT07069725Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWJun 26, 2026NCT07610837lastUpdatePostDate: changed

Frequently asked questions about AZD2389

What is AZD2389 used for?

AZD2389 is an investigational small molecule being developed by AstraZeneca for gastrointestinal conditions, including liver fibrosis, hepatic impairment, and advanced chronic liver disease. It is currently in Phase 1 clinical development, with studies conducted in healthy participants and those with liver-related conditions.

Who makes AZD2389?

AZD2389 is being developed by AstraZeneca PLC, a multinational pharmaceutical company traded on the NASDAQ under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials, with studies focused on healthy participants and individuals with hepatic impairment or advanced chronic liver disease.

What phase is AZD2389 in?

AZD2389 is in Phase 1 clinical development. It has completed several Phase 1 studies, including trials in healthy participants and those with hepatic impairment. The drug is investigational and has not been approved by regulatory authorities, as it is still undergoing early-stage clinical evaluation.

What clinical trials is AZD2389 in?

AZD2389 has been studied in several Phase 1 trials, including NCT06138795, a single and multiple ascending dose study in healthy participants; NCT06812780, a hepatic impairment study; NCT06846528, a drug interaction study with itraconazole; and NCT06973005, a study examining interactions with midazolam, caffeine, and bupropion.

Is AZD2389 the same as any other drug?

No alternative names for AZD2389 have been reported. It is identified solely by its development code AZD2389, and no other brand names or aliases are currently associated with this investigational compound.